Cidara Therapeutics Shares Surge 42% After Re-Acquiring Flu Asset

Dow Jones04-25

By Ben Glickman

Shares of Cidara Therapeutics rose sharply after the company announced a reshuffling of its portfolio of drug candidates.

The stock was up 42% to $17.50 in after-hours trading, following a 20% jump in Wednesday's regular session. Shares are up roughly 15-fold since the start of the year.

The biotechnology company said that it was divesting a candidiasis treatment to its partner and was buying back the license to its potential influenza-prevention treatment.

Cidara expects the divestiture of rezafungin, sold under brand name Rezzayo, to save the company about $128 million over the life of the patent, more than half of which is clinical development costs.

Meanwhile, the company bought back the exclusive rights to its immunotherapy CD388, which is being developed to prevent all strains of the flu, from Johnson & Johnson's Janssen Pharmaceuticals.

The company said it would develop CD388 using the proceeds from a $240 million private stock placement, which was made concurrent with the deal with Janssen.

Write to Ben Glickman at ben.glickman@wsj.com

(END) Dow Jones Newswires

April 24, 2024 19:01 ET (23:01 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2430497742?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-04-25 07:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2430497742","market":"sh","top_or_hot":-1,"title":"Cidara Therapeutics Shares Surge 42% After Re-Acquiring Flu Asset","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Ben Glickman \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of Cidara <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> rose sharply after the company announced a reshuffling of its portfolio of drug candidates. \n</p>\n<p>\n  The stock was up 42% to $17.50 in after-hours trading, following a 20% jump in Wednesday's regular session. Shares are up roughly 15-fold since the start of the year. \n</p>\n<p>\n  The biotechnology company said that it was divesting a candidiasis treatment to its partner and was buying back the license to its potential influenza-prevention treatment. \n</p>\n<p>\n  Cidara expects the divestiture of rezafungin, sold under brand name Rezzayo, to save the company about $128 million over the life of the patent, more than half of which is clinical development costs. \n</p>\n<p>\n  Meanwhile, the company bought back the exclusive rights to its immunotherapy CD388, which is being developed to prevent all strains of the flu, from Johnson &amp; Johnson's Janssen Pharmaceuticals. \n</p>\n<p>\n  The company said it would develop CD388 using the proceeds from a $240 million private stock placement, which was made concurrent with the deal with Janssen. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Ben Glickman at ben.glickman@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 24, 2024 19:01 ET (23:01 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cidara Therapeutics Shares Surge 42% After Re-Acquiring Flu Asset</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCidara Therapeutics Shares Surge 42% After Re-Acquiring Flu Asset\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-25 07:01 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>By Ben Glickman \n\n\n \n\n\n  Shares of Cidara Therapeutics rose sharply after the company announced a reshuffling of its portfolio of drug candidates. \n\n\n  The stock was up 42% to $17.50 in after-hours ...</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0466842654.USD","symbol_name":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"A\" (USD) ACC","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2430497742","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2430497742","pubTimestamp":1713999660,"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Cidara Therapeutics rose sharply after the company announced a reshuffling of its portfolio of drug candidates.The stock was up 42% to $17.50 in after-hours trading, following a 20% jump in Wednesday's regular session. Shares are up roughly 15-fold since the start of the year.The biotechnology company said that it was divesting a candidiasis treatment to its partner and was buying back the license to its potential influenza-prevention treatment.Cidara expects the divestiture of rezafungin, sold under brand name Rezzayo, to save the company about $128 million over the life of the patent, more than half of which is clinical development costs.Meanwhile, the company bought back the exclusive rights to its immunotherapy CD388, which is being developed to prevent all strains of the flu, from Johnson & Johnson's Janssen Pharmaceuticals.The company said it would develop CD388 using the proceeds from a $240 million private stock placement, which was made concurrent with the deal with ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0466842654.USD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"A\" (USD) ACC","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","LU1032466523.USD":"高盛全球多资产收益组合Acc","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","LU1196500208.SGD":"NORDEA STABLE RETURN \"HB\" (SGDHDG) ACC","LU0882574055.USD":"富达全球健康医疗A ACC","LU1059921491.USD":"NORDEA 1 GLOBAL STABLE EQUITY \"HB\" (USDHDG) ACC","BK4559":"巴菲特持仓","LU0122379950.USD":"贝莱德世界健康科学A2","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","BK4568":"美国抗疫概念","LU1244550221.USD":"FRANKLIN GLOBAL MULTI-ASSET  INCOME \"A\" (USDHEDGED) INC (M)","BK4588":"碎股","BK4550":"红杉资本持仓","LU1074936037.SGD":"JPMorgan Funds - US Value A (acc) SGD","LU2133065610.SGD":"JPMorgan Investment Funds - Global Dividend A (mth) SGD","SG9999001440.SGD":"United Global Dividend Equity Fund A SGD Dist","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","LU0795875169.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD-H","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","LU0889566641.SGD":"FTSF - Templeton Shariah Global Equity A Acc SGD","CDTX":"Cidara Therapeutics, Inc.","BK4504":"桥水持仓","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU2347655156.SGD":"JPMorgan Investment Funds - Global Income A (icdiv) SGD-H","IE00B7SZLL34.SGD":"Legg Mason ClearBridge - Value A Acc SGD-H","LU0792757196.USD":"TEMPLETON SHARIAH GLOBAL EQUITY FUND \"A\" (USD) ACC","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","LU0912757837.SGD":"JPMorgan Investment Funds - Global Income A (mth) SGD-H","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU1732800096.USD":"摩根大通环球收益基金A (irc)","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU0640476718.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQ \"AU\" (USD) ACC","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","LU1280957306.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQUITIES \"AUP\" (USD) INC","BK4532":"文艺复兴科技持仓","BK4592":"伊斯兰概念","LU1221951046.USD":"NORDEA 1 STABLE RETURN \"HM\" (USDHDG) INC","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","LU1935042991.SGD":"MANULIFE GF GLOBAL MULTI-ASSET DIVERSIFIED INCOME  \"AA\" (SGDHDG) INC","LU0234572021.USD":"高盛美国核心股票组合Acc","BK4585":"ETF&股票定投概念","JNJ":"强生","SG9999002232.USD":"Allianz Global High Payout USD","LU1267930813.SGD":"FRANKLIN TEMPLETON SHARIAH GLOBAL EQUITY \"AS\" (SGD) ACC","BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4007":"制药","LU0795875086.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD"},"translate_title":"重新收购流感资产后，Cidara Therapeutics股价飙升42%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CDTX":1,"JNJ":0.9},"content_text":"By Ben Glickman \n\n\n \n\n\n  Shares of Cidara Therapeutics rose sharply after the company announced a reshuffling of its portfolio of drug candidates. \n\n\n  The stock was up 42% to $17.50 in after-hours trading, following a 20% jump in Wednesday's regular session. Shares are up roughly 15-fold since the start of the year. \n\n\n  The biotechnology company said that it was divesting a candidiasis treatment to its partner and was buying back the license to its potential influenza-prevention treatment. \n\n\n  Cidara expects the divestiture of rezafungin, sold under brand name Rezzayo, to save the company about $128 million over the life of the patent, more than half of which is clinical development costs. \n\n\n  Meanwhile, the company bought back the exclusive rights to its immunotherapy CD388, which is being developed to prevent all strains of the flu, from Johnson & Johnson's Janssen Pharmaceuticals. \n\n\n  The company said it would develop CD388 using the proceeds from a $240 million private stock placement, which was made concurrent with the deal with Janssen. \n\n\n \n\n\n  Write to Ben Glickman at ben.glickman@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 24, 2024 19:01 ET (23:01 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2430497742"}